Royalty Pharma Announces Q3 2025 Dividend of $0.22 per Share

Royalty Pharma declares a $0.22 per Class A ordinary share dividend for Q3 2025, payable on Sept. 10 to shareholders of record by Aug. 15. The company has a portfolio of royalties on over 35 commercial products, including Vertex's Trikafta and GSK's Trelegy, and 16 development-stage product candidates. Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry.

Royalty Pharma (Nasdaq: RPRX) has announced its quarterly dividend payment for the third quarter of 2025. The company will distribute a dividend of $0.22 per Class A ordinary share, payable on September 10, 2025, to shareholders who are registered as of the record date on August 15, 2025 [1][2].

The board of directors of Royalty Pharma plc approved the dividend payment, which is a continuation of the company's commitment to distributing a portion of its earnings to shareholders. This dividend represents a significant portion of the company's earnings, reflecting its strong financial performance and commitment to shareholder value.

Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. The company has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators [1][2].

The company's current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 16 development-stage product candidates. These products cover a wide range of therapeutic areas, demonstrating Royalty Pharma's broad exposure to the biopharmaceutical market.

Royalty Pharma's dividend policy is an important aspect of its strategy to generate value for shareholders. The company's strong portfolio and commitment to innovation position it well to continue generating significant cash flows, which can be distributed to shareholders in the form of dividends.

For more information, visit www.royaltypharma.com.

References:
[1] https://www.stocktitan.net/news/RPRX/royalty-pharma-declares-third-quarter-2025-eiym7sqonjkp.html
[2] https://www.marketscreener.com/news/royalty-pharma-declares-third-quarter-2025-dividend-ce7c5cdedf8cf121